PRIME MEMBER EXCLUSIVE | 3 Months Free Trial

Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.
Biotech Daily: 5-minute briefing cover art

Biotech Daily: 5-minute briefing

Biotech Daily: 5-minute briefing

Written by: Pod Pub
Listen for free

A daily audio briefing on the most important biotech stories, from new research and clinical signals to regulation, markets, manufacturing, and bioethics.Pod Pub Biological Sciences Science
Episodes
  • Biotech Briefing for 03 June: Antibody Platform, Biotech Funding

    Biotech Briefing for 03 June: Antibody Platform, Biotech Funding
    Jun 3 2026

    Biotech Briefing is a daily audio summary of actionable biotech innovation, research, regulation, markets, and society debates from r/biotechnology and r/biotech. This 2-story episode draws from biotech and moves through antibody platform, biotech funding.

    1. Antibody Platform

    May brought another wave of antibody-focused biotech deals, and the pattern is hard to miss: large drugmakers are still paying heavily for platforms that can make antibodies more targeted, more multifunctional, or easier to combine with other immune tools. The biggest signals came from Pfizer and Innovent, with a collaboration covering up to 12 antibody drugs, and Bristol Myers Squibb and Hengrui, with a 13-asset agreement spanning oncology, hematology, and immunology.

    Source link

    Discussion thread

    Source subreddit: biotech

    2. Biotech Funding

    The White House is moving to change how federal science grants are approved, and the proposal could give political appointees more power over research funding decisions. Under the reported rule change, expert peer review would still happen, but it would become advisory, with senior appointees able to screen awards before money goes out.

    Source link

    Discussion thread

    Source subreddit: biotech

    That's it for this Biotech Briefing.
    Show More Show Less
    4 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet